Savannah Chrisley dismisses backlash over fianc Jason Galais with Instagram hard-launch: Forever adventure partner
Collin Gosselin calls out reality TV producers for putting ratings ahead of kids: 'The show must go on'
An experimental obesity drug significantly reduced breathing interruptions and other symptoms of obstructive sleep disorder in two clinical trials, according to new research published in The New England Journal of Medicine.Obstructive sleep apnea (OSA) affects more than 50 million Americans, and about 80% of cases are undiagnosed, according to the National Sleep Foundation.The study examined whether retatrutide, an investigational weight-loss drug from Eli Lilly, could help treat OSA in adults who were overweight or obese.EXPERIMENTAL OBESITY DRUG OUTPERFORMS TRADITIONAL WEIGHT-LOSS TREATMENTS IN EARLY RESEARCHRetatrutide is being evaluated in phase 3 TRIUMPH trials as a potential treatment for obesity and related metabolic conditions.The drug has not been approved by the FDA.The FDA has warned that unauthorized versions of retatrutide have been illegally marketed and sold online for weight loss.The researchers measured changes in the apnea-hypopnea index (AHI), which counts breathing interruptions per hour of sleep.
(iStock)The two phase 3 randomized trials included 691 adults with moderate-to-severe sleep apnea and a BMI of at least 27.Participants received once-weekly injections of retatrutide at doses of 4, 9 or 12 milligrams, or a placebo, and were followed for 80 weeks.The trials included 243 participants without type 2 diabetes and 448 with the condition.WEIGHT-LOSS DRUGS MAY FIGHT 7 SERIOUS HEALTH PROBLEMS BEFORE THE POUNDS EVEN COME OFFParticipants who received retatrutide lost between 12% and nearly 20% of their body weight and experienced significantly fewer breathing interruptions than those who received a placebo.About 68% of participants experienced more than a 50% improvement in OSA symptoms, regardless of whether they had type 2 diabetes.Retatrutide improved more than 50% of OSA symptoms in 68% of participants over the 80-week period.
(iStock)The study also found that hypoxic burden — the severity and duration of low-oxygen episodes caused by bre...